Dr. Pierre-Henri Benhamou
Dr. Pierre-Henri Benhamou co-founded DBV in 2002, and has served as Chief Executive Officer from 2002-2006 and 2010-present. He was appointed Chairman of the Board of Directors in March 2012. From 2006 to 2010, Dr. Benhamou served as Chief Scientific Officer of DBV. Along with Dr. Christophe Dupont and Bertrand Dupont, Pierre-Henri Benhamou invented and patented the epicutaneous method of immunotherapy and the Viaskin® technology. Before co-founding DBV, Dr. Benhamou was a practicing physician, specializing in pediatric gastroenterology, and has held numerous clinical and academic positions. In 2003, he received the Altran Foundation Prize for Innovation for his work on the development of diagnostic patch tests. Dr. Benhamou has published numerous papers, originated key scientific collaborations for DBV, and has been instrumental in forming the Company’s Scientific Advisory Board. Dr. Benhamou received an M.D. from Faculté de Médecine de Paris in 1984 and his specialization degree in Pediatrics in 1987.
Bertrand Dupont has served as Senior Executive Vice President, Technology since January 2015 and is in charge of the continued development of electrospray and upscaling of production tools. He is also a member of the Executive Committee. Dupont previously served as Chief Technical Officer from 2002-2015. From 1977 to 2002, Dupont served as a high school and university professor teaching mechanics and robotics. Since 2000, he has been at the core of the development of the Viaskin patch and its potential applications. Dupont is a key figure in the development of the Viaskin technology and application systems. He is responsible for every technical aspect of development around the Viaskin technology, including the design of the Viaskin patch, in-house industrial patch filling processes and the design and building of the machines developed by DBV Technologies. Dupont is also responsible for the production of the finished product in DBV partnered CMO facilities. Dupont received an engineering degree from the School of Arts et Métiers of Paris in 1974 and an Aggregation in mechanical engineering in 1987.
David Schilansky was appointed Chief Operating Officer and deputy Chief Executive Officer in January 2015, and is a member of the Board of Directors and Executive Committee. In this role, he supports the CEO in all strategic initiatives and corporate governance matters, supervising Strategy and Finance, Human Resources, Legal, Communications, as well as Business Development. Mr. Schilansky joined DBV as Chief Financial Officer in December 2011. Previously, Schilansky held various senior positions at Ipsen Pharma, including Interim Chief Financial Officer. Earlier in his career, he spent three years at Thomson Inc. (now Technicolor S.A.) as co-head of investor relations and three years at Warburg Dillon Read (now UBS) in the field of mergers and acquisitions. Mr. Schilansky received a master’s degree from Université de Paris Dauphine and a post-graduate degree from Imperial College in London.
Laurent Martin has served as Chief Development Officer since January 2016, and is a member of the Executive Committee. Laurent has held several leadership positions since joining the company in 2007, including Senior Executive Vice President, Product Strategy & Regulatory Affairs and Director of Regulatory Affairs & Quality. Prior to joining DBV, Laurent held various positions at Orphan Europe including Director of Pharmaceutical and Pre-Clinical Development, and Quality Assurance Director together with the role of Interim Responsible Pharmacist (Qualified Person). Earlier in his career, he held roles within Global Regulatory Affairs at Galderma and Guerbet. Laurent received his PharmD from the Université René Descartes in Paris, an M.B.A. from IAE Paris Sorbonne and a Master of Law in Public Health from the faculty of Sceaux
Charles Ruban has served as President North America and Chief Commercial Officer since January 2016, and is a member of the Executive Committee. He joined DBV in June 2012 as Chief Development Officer to lead all development activities. Ruban currently oversees North American Operations and supporting the US launch of Viaskin Peanut and potential follow-on products. Prior to joining DBV, from 2003 to 2012, Ruban held various executive positions at Stallergènes S.A., including Senior Vice President of Product Development leading to several product launches in the EU, the US, and Japan. From 1994 to 2003, Mr. Ruban spent nine years at Eurogroup Consulting as a management and strategy consultant for international industrial clients, including healthcare companies. Mr. Ruban received an Engineering degree from the Ecole Centrale de Lyon, trained at Harvard-MIT Division of Health Sciences and Technology for his Biomedical Engineering Master of Science, and received an Executive MBA from INSEAD.
Dr. Hugh Sampson
Dr. Hugh A. Sampson was appointed Chief Scientific Officer in June 2015 and is a member of the Company’s Scientific Advisory Board. Dr. Sampson maintains his positions as the Director of the Jaffe Food Allergy Institute at Mount Sinai and the Kurt Hirschhorn Professor of Pediatrics, and continues to see patients in clinical practice and direct his basic and translational research programs in food allergy and anaphylaxis. In his role as CSO, Dr. Sampson leads DBV’s research team, pursuing potential new applications of Viaskin for the treatment of food allergies, while also supporting the Company’s clinical development teams. Dr. Sampson is past chair of the Section on Allergy & Immunology of the American Academy of Pediatrics and the past-president of the American Academy of Allergy, Asthma and Immunology. He received his M.D. from the State University of New York at Buffalo School of Medicine and his allergy/immunology fellowship at Duke University.
Dr. Lucia Septién
Dr. Lucia Septién was appointed Chief Medical Officer in July 2016 and is a member of the Company’s Executive Committee. Dr. Septién is responsible for the Company’s clinical development programs, medical affairs, global safety and medical operations and she also has a strategic role in accelerating the development of Viaskin product candidates. Dr. Septién has more than 20 years of experience in the pharmaceutical industry. Prior to joining DBV, Septién was Vice President, Global Neurosciences at Ipsen, responsible for the Medical Strategy of the Botulinum Toxin portfolio. Prior to Ipsen, Dr. Septién served as Vice President of the Specialty Care Business Unit, Europe, at Pfizer. Prior to Pfizer, she served at Wyeth Pharma as Assistant Vice President, Global Neuroscience. Dr. Septién earned her medical degree at the National University of Mexico City, specializing in Psychiatry. She completed her post-graduate training in Nuclear Medicine at the Commisariat de l'Energie Atomique in Saclay, France.